Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales).

Patient Support

Patient Support across our Therapeutic Areas

Diabetes

Dyslipidaemia

Neurology

Oncology

Rare Blood Disorders

Rare Diseases

Thrombosis

Vaccines

Supporting your Patients

Articles and materials to support your patients’ needs

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

ItsInYourMuscles

Patient Support

Introduce your patients to this muscle disease awareness site.

Multiple Sclerosis

Homecare | Praluent® alirocumab

Patient Support

Patient Resources | Praluent® alirocumab

Patient Support

Patient Profiles | Praluent® alirocumab

Patient Support

MyPraluent® Coach | Praluent® alirocumab

Patient Support

Nexviadyme ▼ (avalglucosidase alfa) website

Information for patients prescribed Nexviadyme

Fabry disease and self-care

Patient Support

Fabry disease and the 5-2-21 method

Patient Support

MPS I Physiotherapy Flipbook

Resources and Tools

Resources, tools and links to help you support your patients

Patient Organisation website

Discover more about the UK-based charity dedicated to raising awareness of Gaucher disease.

Cerdelga▼(eliglustat) Patient Materials

Patient Support

Access downloadable materials for patients who have been prescribed Cerdelga

MPS I Disease Awareness Slide Deck

This slide deck will support you in developing your knowledge of MPS I.

Rare Blood Disorders Patient Support

Discover support resources provided by this patient-led organisation.

Diagnostic Algorithms for Gaucher disease

Patient Support

Learn more about the diagnostic algorithms for Gaucher disease.

Downloadable PDF: Signs & Symptoms of Gaucher disease

Patient Support

Learn more about the signs and symptoms of Gaucher disease.

Our Products

ADMELOG
insulin lispro

Prescribing Information GB
GB ONLY CONTENT

MAT-GB-2105789 (v6.0)
Date of preparation: February 2023

ALDURAZYME
laronidase

Prescribing Information GB
Prescribing Information NI

MAT-XU-2200954 (v2.0)
Date of preparation: February 2023

AUBAGIO
teriflunomide

Prescribing Information GB
Prescribing Information NI

MAT-XU-2200676 (v4.0)
Date of preparation: April 2023

AVAXIM^® Junior

Prescribing Information UK

MAT-XU-2301296 (v1.0)
Date of preparation: April 2023

Prescribing Information UK

MAT-XU-2301117 (v1.0)
Date of preparation: April 2023

Cablivi
caplacizumab

Prescribing Information GB
Prescribing Information NI

MAT-GB-2105168 (v5.0)
Date of preparation: May 2023

CERDELGA
eliglustat 84mg

Prescribing Information GB
Prescribing Information NI

MAT-XU-2204064 (v2.0)
Date of preparation: January 2023

CEREZYME
imiglucerase

Prescribing Information GB
Prescribing Information NI

MAT-XU-2204065 (v2.0)
Date of preparation: January 2023

Clexane
enoxaparin

Prescribing Information UK

MAT-XU-2204397 (v2.0)
Date of preparation: May 2023

Fabrazyme
agalsidase beta

Prescribing Information GB
Prescribing Information NI

MAT-GB-2105812 (v4.0)
Date of preparation: May 2023

LANTUS
insulin glargine

Prescribing Information GB
Prescribing Information NI

MAT-XU-2201444 (v3.0)
Date of preparation: January 2023

LEMTRADA
Alemtuzumab

Prescribing Information GB
Prescribing Information NI

MAT-XU-2200680 (v2.0)
Date of preparation: August 2022

Prescribing Information GB
Prescribing Information NI

MAT-XU-2202651 (v1.0)
Date of preparation: February 2023

Menquadfi^TM

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301129 (v1.0)
Date of preparation: May 2023

MYOZYME
alglucosidase alfa

Prescribing Information GB
Prescribing Information NI

MAT-GB-2105179 (v3.0)
Date of preparation: February 2023

NEXVIADYME
avalglucosidase alfa

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2203480 (v3.0)
Date of preparation: February 2023

PRALUENT
alirocumab

Prescribing Information GB
Prescribing Information NI

MAT-XU-2204604 (v2.0)
Date of preparation: March 2023

Prescribing Information UK

MAT-XU-2301127 (v1.0)
Date of preparation: May 2023

Prescribing Information UK

MAT-XU-2301125 (v1.0)
Date of preparation: May 2023

Prescribing Information UK

MAT-XU-2301123 (v1.0)
Date of preparation: May 2023

REZUROCK
belumosudil tablets

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2202695 (v2.0)
Date of preparation: April 2023

SARCLISA
isatuximab

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2202578 (v1.0)
Date of preparation: May 2023

STAMARiL^®

Prescribing Information UK

MAT-XU-2301130 (v1.0)
Date of preparation: May 2023

Supemtek^®

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301126 (v1.0)
Date of preparation: May 2023

TOUJEO
insulin glargine

Prescribing Information UK

MAT-GB-2105435 (v7.0)
Date of preparation: May 2023

TRURAPI
insulin aspart

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2205461 (v6.0)
Date of preparation: April 2023

TYPHIM Vi^®

Prescribing Information UK

MAT-XU-2301128 (v1.0)
Date of preparation: May 2023

Prescribing Information GB
GB ONLY CONTENT

MAT-XU-2301124 (v1.0)
Date of preparation: May 2023

▼ This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.

MAT-XU-2301218 (v2.0)
Date of preparation: May 2023

YOU ARE NOW LEAVING THE SANOFI CAMPUS UK WEBSITE

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

Continue

Welcome to Sanofi Campus UK

This site is intended for UK healthcare professionals only and contains information on Sanofi UK’s medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales).

MAT-XU-2300297 (v1.0)
Date of Preparation: February 2023